VCEL stock forecast
Our latest prediction for Vericel Corp.'s stock price was made on the March 11, 2019 when the stock price was at 20.10$.
In the short term (2weeks), VCEL's stock price should outperform the market by 1.00%. During that period the price should oscillate between -6.58% and +7.62%.
In the medium term (3months), VCEL's stock price should outperform the market by 3.51%. During that period the price should oscillate between -14.89% and +23.77%.Get email alerts
About Vericel Corp.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns comprising a total body surface area of greater than or equal to 30%. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
At the moment the company generates 91M USD in revenues.
On its last earning announcement, the company reported a loss of -0.20$ per share.
The book value per share is 2.12$
Three months stock forecastMarch 11, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|